Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 6/20 | 0.71 |
| ▸ | ANPEP | P15144 | 3/20 | 0.71 |
| ▸ | PLAU | P00749 | 6/20 | 0.69 |
| ▸ | PLAT | P00750 | 5/20 | 0.50 |
| ▸ | F2 | P00734 | 4/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KLK8 | O60259 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | KLK2 | P20151 | 1/20 | 0.45 |
| ▸ | KLK4 | Q9Y5K2 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242403 | 0.84 | PLAU (0.67) | LAP3ANPEPPLAUPLATF2 | |
| SCHEMBL12354630 | 0.81 | PLAU (0.62) | LAP3ANPEPPLAUPLATF2 | |
| SCHEMBL28659355 | 0.80 | ANPEP (0.53) | LAP3ANPEPPLAUELANEMEN1 | |
| SCHEMBL11167921 | 0.80 | LAP3 (0.70) | LAP3ANPEPPLAUEPHX1 | |
| SCHEMBL7423000 | 0.77 | ANPEP (0.50) | LAP3ANPEPPLAUELANEMEN1 | |
| SCHEMBL7417923 | 0.77 | ANPEP (0.71) | LAP3ANPEPPLAUELANEMEN1 | |
| SCHEMBL6976815 | 0.77 | LAP3 (0.57) | LAP3ANPEPPLAUMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11127095 | 0.76 | LAP3 (0.55) | LAP3ANPEPPLAUMEN1KMT2A | |
| SCHEMBL7723777 | 0.75 | ANPEP (0.48) | LAP3ANPEPPLAU | |
| SCHEMBL22006008 | 0.74 | PLAU (0.61) | LAP3ANPEPPLAUPLATF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230248000-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | AEQUOR, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230248000-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | AEQUOR, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| WO-2022081594-A1 | ANTIMICROBIAL COMBINATION THERAPEUTICS | AEQUOR, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3653215-A1 | THERANOSTIC INHIBITORS AND ACTIVITY-BASED PROBES FOR THE KLK7 PROTEASE | University of Patras (GR) | 2020-05-20 | — | — | EP | disclosed |
| US-8314215-B2 | Mild chemically cleavable linker system | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-11-20 | — | — | US | disclosed |
| US-20100003735-A1 | Mild Chemically Cleavable Linker System | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2008094205-A2 | A MILD CHEMICALLY CLEAVABLE LINKER SYSTEM | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-08-07 | — | — | WO | disclosed |
| US-5686419-A | SERINE PROTEASE INHIBITOR ANTICOAGULANTS | GEORGIA TECH RESEARCH CORP. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5543396-A | Proline phosphonate derivatives | GEORGIA TECH RESEARCH CORP. (US) | 1996-08-06 | — | — | US | disclosed |
| WO-1995029691-A1 | PROLINE PHOSPHONATE DERIVATIVES | GEORGIA TECH RESEARCH CORPORATION (US) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | LAP3 1301/4885ANPEP 1092/4885PLAU 1334/4885 |
| US-20100003735-A1 | Mild Chemically Cleavable Linker System | BTD, SPR, DDO | LAP3 150/4885ANPEP 45/4885PLAU 1427/4885 |
| US-20230248000-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | DDT, PFAS, CASP10 | LAP3 1334/4885ANPEP 723/4885PLAU 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.